Chapter 12
Natural Killer/T-cell Lymphomas
Seok Jin Kim,
Ritsuro Suzuki,
Arnaud Jaccard,
Soon Thye Lim,
Won Seog Kim,
Seok Jin Kim
Division of Hematology and Oncology, Sungkyunkwan, University School of Medicine, Samsung Medical Center, Seoul, Korea
Search for more papers by this authorRitsuro Suzuki
Department of Oncology and Hematology, Shimane University Hospital, Izumo, Japan
Search for more papers by this authorArnaud Jaccard
Service d'Hématologie et de Thérapie Cellulaire, Hôpital Dupuytren, CHU de Limoges, Limoges, France
Search for more papers by this authorSoon Thye Lim
Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore
Search for more papers by this authorWon Seog Kim
Division of Hematology and Oncology, Sungkyunkwan, University School of Medicine, Samsung Medical Center, Seoul, Korea
Search for more papers by this authorSeok Jin Kim,
Ritsuro Suzuki,
Arnaud Jaccard,
Soon Thye Lim,
Won Seog Kim,
Seok Jin Kim
Division of Hematology and Oncology, Sungkyunkwan, University School of Medicine, Samsung Medical Center, Seoul, Korea
Search for more papers by this authorRitsuro Suzuki
Department of Oncology and Hematology, Shimane University Hospital, Izumo, Japan
Search for more papers by this authorArnaud Jaccard
Service d'Hématologie et de Thérapie Cellulaire, Hôpital Dupuytren, CHU de Limoges, Limoges, France
Search for more papers by this authorSoon Thye Lim
Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore
Search for more papers by this authorWon Seog Kim
Division of Hematology and Oncology, Sungkyunkwan, University School of Medicine, Samsung Medical Center, Seoul, Korea
Search for more papers by this authorBook Editor(s):Owen A. O'Connor M.D., Ph.D.,
Won Seog Kim,
Pier Luigi Zinzani M.D., Ph.D.,
Owen A. O'Connor M.D., Ph.D.
American Cancer Society Research Professor Professor of Medicine
Department of Medicine, Division of Hematology and Oncology, Program for T-Cell Lymphoma Research, Department of Microbiology, Immunology, and Cancer Research, University of Virginia Cancer Center, Charlottesville, VA, USA
Search for more papers by this authorWon Seog Kim
Sungkyunkwan University School of Medicine, Seoul, Korea
Search for more papers by this authorPier Luigi Zinzani M.D., Ph.D.
Professor of Hematology
Department of Medicine, Program for Lymphomas and Chronic Lymphocytic Leukemia, University of Bologna, Bologna, Italy
Search for more papers by this authorFirst published: 19 February 2021
Summary
Natural killer (NK)-cell lymphomas are rare hematological malignancies. Extranodal natural killer/T-cell lymphoma is an Epstein–Barr virus-associated lymphoma with skewed geographic distribution, which is more common in East Asia and central and southern America. Extranodal NK/T-cell lymphoma (ENKTL), nasal type, and aggressive NK-cell lymphoma (ANKL) are defined in the current World Health Organization classification. During the past decade, impressive progress in the understanding of the biology, clinical features, and treatment options for ENKTL has been made. Hematopoietic stem-cell transplantation (HSCT) is not used as the first line of defense in patients with localized disease who should receive adequate treatment including radiation and chemotherapy. Patients with disseminated disease are candidates for HSCT, and intensive polychemotherapy followed by auto- or allogeneic HSCT, can be considered as standard care.
References
- Chan, J.K.C., Quintanilla-Martinez, L., and Ferry, J.A.(eds. S.H. Swerdlow, E. Campo, N.L. Harris, et al.). Extranodal NK/T-cell lymphoma, nasal type. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 368–371. Lyon: International Agency for Research on Cancer.
- Chan, J.K.C., Jaffe, E.S., and Ko, Y.H. (2017). Aggressive NK-Cell Leukemia, in WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (eds. S.H. Swerdlow, E. Campo, N.L. Harris, et al.), 353–354. Lyon: International Agency for Research on Cancer.
- Lee, J., Suh, C., Park, Y.H. et al. (2006). Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 24 (4): 612–618.
- Au, W.Y., Weisenburger, D.D., Intragumtornchai, T. et al. (2009). Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 113 (17): 3931–3937.
- Yamaguchi, M., Tobinai, K., Oguchi, M. et al. (2009). Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol 27 (33): 5594–5600.
- Kim, Kim, S.J., Kim, K., Kim, B.S. et al. (2009). Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study. J Clin Oncol 27 (35): 6027–6032.
- Yamaguchi, M., Kwong, Y.L., Kim, W.S. et al. (2011). Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol 29 (33): 4410–4416.
- Yamaguchi, M., Suzuki, R., Oguchi, M. et al. (2017). Treatments and outcomes of patients with extranodal natural killer/T-cell lymphoma diagnosed between 2000 and 2013: a cooperative study in Japan. J Clin Oncol 35 (1): 32–39.
- Kim, S.J., Yoon, D.K., Jaccard, A. et al. (2016). A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncol 17 (3): 389–400.
- Suzuki, R., Suzumiya, J., Nakamura, S. et al. (2004). Aggressive natural killer-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells. Leukemia 18 (4): 763–770.
- Ishida, F., Ko, Y.H., Kim, W.S. et al. (2012)). Aggressive natural killer cell leukemia: therapeutic potential of L-asparaginase and allogeneic hematopoietic stem cell transplantation. Cancer Sci 103 (6): 1079–1083.
- Lymphoma Study Group of Japanese Pathologists (2000)). The World Health Organization classification of malignant lymphomas in Japan: incidence of recently recognized entities. Pathol Int 50 (9): 696–702.
- Peh, S.C. (2001). Host ethnicity influences non-Hodgkin's lymphoma subtype frequency and Epstein-Barr virus association rate: the experience of a multi-ethnic patient population in Malaysia. Histopathology 38 (5): 458–465.
-
Sukpanichnant, S., Sonakul, D., Piankijagum, A. et al. (1998). Malignant lymphoma in Thailand: changes in the frequency of malignant lymphoma determined from a histopathologic and immunophenotypic analysis of 425 cases at Siriraj hospital. Cancer
83 (6): 1197–1204.
10.1002/(SICI)1097-0142(19980915)83:6<1197::AID-CNCR20>3.0.CO;2-# CAS PubMed Web of Science® Google Scholar
- Chen, C.Y., Yao, M., Tng, J.L. et al. (2004). Chromosomal abnormalities of 200 Chinese patients with non-Hodgkin's lymphoma in Taiwan: with special reference to T-cell lymphoma. Ann Oncol 15 (7): 1091–1096.
- Au, W.Y., Ma, S.Y., Chim, C.S. et al. (2005). Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years. Ann Oncol 16 (2): 206–214.
-
Ko, Y.H., Kim, C.W., Park, C.S. et al. (1998). REAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features. Hematolymphoreticular Study Group of the Korean Society of Pathologists. Revised European-American lymphoma. Cancer
83 (4): 806–812.
10.1002/(SICI)1097-0142(19980815)83:4<806::AID-CNCR26>3.0.CO;2-V CAS PubMed Web of Science® Google Scholar
- Sun, J., Yang, Q., Lu, Z. et al. (2012). Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification. Am J Clin Pathol 138 (3): 429–434.
- Non-Hodgkin's Lymphoma Classification Project (1997). A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 89 (11): 3909–3918.
- Naresh, K.N., Srinivas, V., and Soman, C.S. (2000). Distribution of various subtypes of non-Hodgkin's lymphoma in India: a study of 2773 lymphomas using R.E.A.L. and WHO classifications. Ann Oncol 11 (Suppl 1): 63–67.
- Turner, J.J., Hughes, A.M., Kricker, A. et al. (2004). Use of the WHO lymphoma classification in a population-based epidemiological study. Ann Oncol 15 (4): 631–637.
- Economopoulos, T., Papageorgiou, S., Dimopoulos, M.A. et al. (2005). Non-Hodgkin's lymphomas in Greece according to the WHO classification of lymphoid neoplasms: a retrospective analysis of 810 cases. Acta Haematol 113 (2): 97–103.
- Au, W.Y., Gascoyne, R.D., Klasa, R.D. et al. (2005). Incidence and spectrum of non-Hodgkin lymphoma in Chinese migrants to British Columbia. Br J Haematol 128 (796): 792–796.
- Aviles, A., Díaz, N.R., Neri, N. et al. (2000). Angiocentric nasal T/natural killer cell lymphoma: a single centre study of prognostic factors in 108 patients. Clin Lab Haematol 22 (4): 215–220.
- Barrionuevo, C., Zaharia, M., Martinez, M.T. et al. (2007). Extranodal NK/T-cell lymphoma, nasal type: study of clinicopathologic and prognosis factors in a series of 78 cases from Peru. Appl Immunohistochem Mol Morphol 15 (1): 38–44.
- Gualco, G., Domeny-Duarte, P., Chioato, L. et al. (2011). Clinicopathologic and molecular features of 122 Brazilian cases of nodal and extranodal NK/T-cell lymphoma, nasal type, with EBV subtyping analysis. Am J Surg Pathol 35 (8): 1195–1203.
- Li, Z., Xia, Y., Feng, L.N. et al. (2016). Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study. Lancet Oncol 17 (9): 1240–1247.
- Kanno, H., Koyja, S., Ohsawa, S. et al. (2000). Low frequency of HLA-A* 0201 allele in patients with Epstein-Barr virus-positive nasal lymphomas with polymorphic reticulosis morphology. Int J Cancer 87 (2): 195–199.
- Chan, J.Y., Ng, A.Y.J., Cheng, C.L. et al. (2018). Whole exome sequencing identifies recessive germline mutations in FAM160A1 in familial NK/T cell lymphoma. Blood Cancer J 8 (11): 111–111.
- Huang, Y., de Reyniès, A., de Leval, L. et al. (2010). Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type. Blood 115 (6): 1226–1237.
- Iqbal, J., Weisenburger, D.D., Chowdhury, A. et al. (2011). Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic γδ T-cell lymphoma and is highly sensitive to a novel aurora kinase a inhibitor in vitro. Leukemia 25 (2): 348–358.
- Ng, S.B., Selvarajan, V., Huang, G. et al. (2011). Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling. J Pathol 223 (4): 496–510.
- Iqbal, J. et al. (2009). Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies. Leukemia 23 (6): 1139–1151.
- Nakashima, Y., Tagawa, H., Suzuki, R. et al. (2005). Genome-wide array-based comparative genomic hybridization of natural killer cell lymphoma/leukemia: different genomic alteration patterns of aggressive NK-cell leukemia and extranodal Nk/T-cell lymphoma, nasal type. Genes Chromosomes Cancer 44 (3): 247–255.
- Dobashi, A., Tsuyama, N., Asaka, R. et al. (2016). Frequent BCOR aberrations in extranodal NK/T-cell lymphoma, nasal type. Genes Chromosomes Cancer 55 (5): 460–471.
- Jiang, L., Gu, Z.H., Yan, Z.X. et al. (2015). Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma. Nat Genet 47 (9): 1061–1066.
- Koo, G.C., Tan, S.Y., Tang, T. et al. (2012). Janus kinase 3–activating mutations identified in natural killer/T-cell lymphoma. Cancer Discov 2 (7): 591–597.
- Lee, S., Park, H.Y., Kang, S.Y. et al. (2015). Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type. Oncotarget 6 (19): 17764–17776.
- Kwong, Y.L., Chan, T.S.Y., Tan, D. et al. (2017). PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. Blood 129 (17): 2437–2442.
- Li, X., Cheng, Y., Zhang, M. et al. (2018). Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma. J Hematol Oncol 11 (1): 15.
- Lim, J.Q., Tang, T., Cai, Q. et al. (2018). Whole-genome genomics correlates of response to anti-PD1 therapy in relapsed/refractory natural killer/T cell lymphoma. bioRxiv: 372383. https://doi.org/10.1101/372383.
- Song, T.L., Nairismägi, M.L., Laurensia, Y. et al. (2018). Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma. Blood 132 (11): 1146–1158.
- Küçük, C., Jiang, B., Hu, X. et al. (2015). Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells. Nat Commun 6 (1): 6025.
- Bouchekioua, A., Scourzic, L., de Wever, O. et al. (2014). JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma. Leukemia 28 (2): 338–348.
- Kimura, H., Karube, K., Ito, Y. et al. (2014). Rare occurrence of JAK3 mutations in natural killer cell neoplasms in Japan. Leuk Lymphoma 55 (4): 962–963.
- Karube, K., Nakagawa, M., Tsuzuki, S. et al. (2011). Identification of FOXO3 and PRDM1 as tumor-suppressor gene candidates in NK-cell neoplasms by genomic and functional analyses. Blood 118 (12): 3195–3204.
- Wong, K.F., Chan, J.K., and Kwong, Y.L. (1997). Identification of del(6)(q21q25) as a recurring chromosomal abnormality in putative NK cell lymphoma/leukaemia. Br J Haematol 98 (4): 922–926.
- Tsai, H.J., Lin, S.F., Chen, C.C. et al. (2015). Long-term results of a phase II trial with frontline concurrent chemoradiotherapy followed by consolidation chemotherapy for localized nasal natural killer/T-cell lymphoma. Eur J Haematol 94 (2): 130–137.
- Wong, A.L., Soo, R.A., Tan, D.S. et al. (2015). Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies. Ann Oncol 26 (5): 998–1005.
- Harrison, C. et al. (2012). JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366 (9): 787–798.
- Yan, J., Li, B., Lin, B. et al. (2016). EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphoma. Blood 128 (7): 948–958.
- Yu, C.R., Kim, S.H., Mahdi, R.M. et al. (2013). SOCS3 deletion in T lymphocytes suppresses development of chronic ocular inflammation via upregulation of CTLA-4 and expansion of regulatory T cells. J Immunol 191 (10): 5036–5043.
- Bian, C., Liu, Z., Li, D. et al. (2018). PI3K/AKT inhibition induces compensatory activation of the MET/STAT3 pathway in non-small cell lung cancer. Oncol Lett 15 (6): 9655–9662.
- Moskowitz, A.J. and Horwitz, S.M. (2017). Targeting histone deacetylases in T-cell lymphoma. Leuk Lymphoma 58 (6): 1306–1319.
- Yan, J., Ng, S.B., Tay, J.L.S. et al. (2013). EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity. Blood 121 (22): 4512–4520.
- Xu, K., Wu, Z.J., Groner, A.C. et al. (2012). EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science 338 (6113): 1465–1469.
- Wen, H., Ma, H., Cai, Q. et al. (2018). Recurrent ECSIT mutation encoding V140A triggers hyperinflammation and promotes hemophagocytic syndrome in extranodal NK/T cell lymphoma. Nat Med 24 (2): 154–164.
- Nagato, T. et al. (2017). Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy. Cancer Immunol Immunother 66 (7): 877–890.
- Jo, J.C., Kim, M., Choi, Y. et al. (2017). Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type. Ann Hematol 96 (1): 25–31.
- Ng, S.-B., Chung, T.H., Kato, S. et al. (2018). Epstein–Barr virus-associated primary nodal T/NK-cell lymphoma shows a distinct molecular signature and copy number changes. Haematologica 103 (2): 278–287.
- Bi, X.W., Wang, H., Zhang, W.W. et al. (2016). PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma. J Hematol Oncol 9 (1): 109.
- Kataoka, K., Shiraishi, Y., Takeda, Y. et al. (2016). Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers. Nature 534 (7607): 402–406.
- Kataoka, K., Miyoshi, H., Sakata, S. et al. (2019). Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas. Leukemia 33 (7): 1687–1699.
- Lim, J.-Q. et al. (2018). Recurrent PD-L1 structural rearrangements in natural killer/T cell lymphoma patients with complete response to PD-1 blockade therapy. bioRxiv: 372383. https://doi.org/10.1101/372383.
- Jaccard, A., Gachard, M., Marin, B. et al. (2011). Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood 117 (6): 1834–1839.
- Wang, L., Wang, H., Wang, J.H. et al. (2015). Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase. Oncotarget 6 (30): 30317–30326.
- Au, W.Y., Pang, A., Choy, C. et al. (2004). Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood 104 (1): 243–249.
- Li, Y.X. et al. (2011)). Failure patterns and clinical implications in early stage nasal natural killer/T-cell lymphoma treated with primary radiotherapy. Cancer 117 (22): 5203–5211.
- Wang, Z.Y., Li, Y.X., Wang, W.H. et al. (2009). Primary radiotherapy showed favorable outcome in treating extranodal nasal-type NK/T-cell lymphoma in children and adolescents. Blood 114 (23): 4771–4776.
- Zang, J., Li, C., Luo, s.Q. et al. (2015). Early radiotherapy has an essential role for improving survival in patients with stage I-II nasal-type of NK/T cell lymphoma treated with L-asparaginase-containing chemotherapy – a single institution experience. Ann Hematol 94 (4): 583–591.
- Kim, S.J., Yang, D.H., Kim, J.S. et al. (2014). Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study. Ann Hematol 93 (11): 1895–1901.
- Michot, J.M., Mazeron, R., Danu, A. et al. (2015). Concurrent etoposide, steroid, high-dose Ara-C and platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type. Eur J Cancer 51 (16): 2386–2395.
- Yoon, D.H., Kim, S.J., Jeong, S.H. et al. (2016). Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008). Oncotarget 7 (51): 85584–85591.
- Ke, Q.H., Zhou, S.Q., Du, W. et al. (2014). Concurrent IMRT and weekly cisplatin followed by GDP chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-cell lymphoma. Blood Cancer J 4: e267.
- Kwong, Y.L., Kim, W.S., Lim, S.T. et al. (2012). SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood 120 (15): 2973–2980.
- Dong, L.H., Zhang, L.J., Wang, W.J. et al. (2016). Sequential DICE combined with l-asparaginase chemotherapy followed by involved field radiation in newly diagnosed, stage IE to IIE, nasal and extranodal NK/T-cell lymphoma. Leuk Lymphoma 57 (7): 1600–1606.
- Wang, L., Wang, Z.H., Chen, X.Q. et al. (2013). First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma. Cancer 119 (2): 348–355.
- Li, J.W., Li, Y.J., Zhong, M.Z. et al. (2018). Efficacy and tolerance of GELOXD/P-GEMOXD in newly diagnosed nasal-type extranodal NK/T-cell lymphoma: a multicenter retrospective study. Eur J Haematol 100 (3): 247–256.
- Kim, S.J., Yoon, S.E., and Kim, W.S. (2018). Treatment of localized extranodal NK/T cell lymphoma, nasal type: a systematic review. J Hematol Oncol 11 (1): 140.
- Wei, W., Wu, P., Li, L. et al. (2017). Effectiveness of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy in newly diagnosed, stage IE to IIE, nasal-type, extranodal natural killer/T-cell lymphoma. Hematology 22 (6): 320–329.
- Kwong, Y.L., Kim, S.J., Tse, E. et al. (2018). Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma. Ann Oncol 29 (1): 256–263.
- Li, X., Chi, Y., Sun, Z. et al. (2016). DDGP versus SMILE in newly diagnosed advanced natural killer/T-cell lymphoma: a randomized controlled, multicenter, open-label study in China. Clin Cancer Res 22 (21): 5223–5228.
- Shi, Y. et al. (2015). Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol 26 (8): 1766–1771.
- Kim, S.J., Dong, M., Hong, X. et al. (2016). Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin. Ann Oncol 27 (3): 508–513.
- Bollard, C.M., Gottschalk, S., Torrano, V. et al. (2014). Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein–Barr virus latent membrane proteins. J Clin Oncol 32 (8): 798–808.
- Lim, S.H., Hong, J.Y., Lim, S.T. et al. (2017). Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease. Ann Oncol 28 (9): 2199–2205.
- Kim, S.J., Park, Y., Kim, B.S. et al. (2012). Extranodal natural killer/T-cell lymphoma with long-term survival and repeated relapses: does it indicate the presence of indolent subtype? Korean J Hematol 47 (3): 202–206.
- Yamaguchi, M., Suzuki, R., Kim, S.J. et al. (2018). Early disease progression in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy. Cancer Sci 109 (6): 2056–2062.
- Chen, J.S., Lin, K.H., Lin, D.T. et al. (1998). Longitudinal observation and outcome of nonfamilial childhood haemophagocytic syndrome receiving etoposide-containing regimens. Br J Haematol 103 (3): 756–762.
- Uno, M., Tsuchiyama, J., Moriwaki, A. et al. (2001). In vitro induction of apoptosis for nasal angiocentric natural killer cell lymphoma-derived cell line, NK-YS, by etoposide and cyclosporine A. Br J Haematol 113 (4): 1009–1014.
- Jaccard, A., Gachard, N., Marin, B. et al. (2008). A prospective phase II trial of an L-Asparaginase containing regimen in patients with refractory or relapsing extra nodal NKJT-cell lymphoma. Blood 112 (11): 217–217.
- Wang, J.J., Dong, H.M., He, X.H. et al. (2016). GDP (gemcitabine, dexamethasone, and cisplatin) is highly effective and well-tolerated for newly diagnosed stage IV and relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type. Medicine (Baltimore) 95 (6): e2787.
- Chan, T.S.Y., Li, J., Loong, F. et al. (2018). PD1 blockade with low-dose nivolumab in NK/T cell lymphoma failing L-asparaginase: efficacy and safety. Ann Hematol 97 (1): 193–196.
- Kim, S.J., Hyeon, J., Cho, I. et al. (2019). Comparison of efficacy of pembrolizumab between Epstein-Barr Virus positive and negative relapsed or refractory non-Hodgkin lymphomas. Cancer Res Treat 51 (2): 611–622.
- Kim, S.J., Yoon, D.H., Kim, J.S. et al. (2019). Efficacy of brentuximab vedotin in relapsed or refractory high-CD30-expressing non-Hodgkin lymphomas: results of a multicenter, open-labeled phase II trial. Cancer Res Treat 52 (2): 374–387.
- Hari, P., Raj, R.V., and Olteanu, H. (2016). Targeting CD38 in refractory extranodal natural killer cell-T-cell lymphoma. N Engl J Med 375 (15): 1501–1502.
